Landmark Nationwide Trial Shows Genome Sequencing Beats Standard Testing for Developmental Disorders

For thousands of families facing an unexplained developmental disorder, the diagnostic odyssey can stretch across years of tests that yield nothing but frustration. Now, one of the largest and most rigorous head-to-head comparisons ever conducted suggests that a single test — whole genome sequencing — could shorten that journey dramatically. In a prospective randomized trial spanning all eight centers for human genetics in Belgium, researchers found that genome sequencing diagnosed significantly more children with developmental disorders, intellectual disability, and congenital anomalies than the current standard of care, which combines exome sequencing with chromosomal microarray or shallow genome sequencing.

The study, known as the BeSolveRD trial and published in Genome Medicine, enrolled 567 individuals with unexplained developmental disorders between June 2021 and July 2024. Participants were randomized using blocked, center-specific lists into two arms: 283 received the standard diagnostic pathway, while 284 received whole genome sequencing. The trial was designed to answer a question that has divided clinical genetics for years — whether the extra information contained in the roughly 90 percent of the genome beyond the exome, the protein-coding fraction, translates into real diagnostic gains in routine hospital settings rather than in centralized reference laboratories.

The headline result was clear. Genome sequencing achieved a diagnostic yield of 39.8 percent, identifying a certain molecular diagnosis in 113 of 284 probands, compared with 30 percent — 85 of 283 — for the standard of care, a difference that was statistically significant (p = 0.015). When the researchers accounted for inherited variants in genes associated with autosomal dominant conditions, the gap widened further, with genome sequencing outperforming standard care by 9.8 percentage points, equivalent to a relative increase in diagnostic yield of 32.7 percent. Most of the added value came from better detection of single nucleotide variants and small insertions or deletions, which contributed an additional 8.7 percent of diagnoses in the genome sequencing arm.

The technical story behind those numbers is instructive. Genome sequencing offers more uniform coverage across the genome than exome sequencing, which relies on capture probes that can miss regions with poor sequence homology to the reference genome. In this trial, the researchers found that the exome data actually covered the genomic loci of nearly all genome-sequencing-detected variants at more than 20-fold depth, suggesting the advantage was not simply a matter of coverage drops. Instead, the most striking difference emerged in the detection of out-of-frame indels: 26 frameshift variants were identified in the genome sequencing arm versus only 10 in the standard care arm, a difference of 5.6 percent that reached statistical significance. The authors hypothesize that variants with lower sequence similarity to the reference genome may be less effectively captured by exome probes, leading to their underrepresentation in sequencing data.

Genome sequencing also uncovered diagnoses that exome-based approaches structurally cannot reach. Three non-coding or otherwise elusive pathogenic variants were detected, including a de novo variant in the 5′ untranslated region of MEF2C, a gene whose regulatory disruption causes severe developmental disorder; a short tandem repeat expansion in the promoter of FMR1, the cause of Fragile-X syndrome, one of the most prevalent forms of inherited intellectual disability in males; and two pathogenic SHANK3 frameshift variants that had been filtered out in routine analysis because of inflated frequency estimates in population databases. A small 5′ untranslated region deletion potentially downregulating ANKRD11, associated with KBG syndrome, was also identified only through genome sequencing. These findings illustrate the growing recognition that the non-coding genome, repeat expansions, and structural variation harbor a meaningful share of disease-causing variants that exome-centric pipelines miss.

Perhaps the most surprising finding of the trial concerned inherited variants. Clinical laboratories analyzing trio data typically prioritize de novo variants, X-linked variants, and autosomal recessive inheritance. But when the researchers systematically examined inherited variants in genes associated with autosomal dominant conditions, they found 22 additional diagnoses across both arms — 3.9 percent of the entire cohort — representing 11 percent of all certain diagnoses. For 18 of these 22 families, there had been no prior suspicion of a dominantly inherited disorder, and half of the carrier parents were reported to be asymptomatic, consistent with the variable expression and reduced penetrance described for these genes. The contribution of inherited dominant variants (3.9 percent) exceeded that of X-linked variants (1.9 percent) and matched that of autosomal recessive variants (4.1 percent). The authors argue this strongly favors including autosomal dominant inherited variants in the standard work-up for developmental disorders, even when parents appear unaffected — a practice with real clinical consequences, as illustrated by two maternally inherited pathogenic PTEN variants that carry implications for lifelong cancer surveillance.

The trial also revealed a striking and persistent sex difference. Females obtained a diagnosis in 45.5 percent of cases, compared with only 28.5 percent of males — a 17 percentage-point gap that remained significant across indication categories and even among probands with moderate to profound intellectual disability. Part of this difference may reflect the higher prevalence of autism and autistic behavior among males, since autism was associated with lower diagnostic yields in this cohort. But the pattern aligns with previous large exome analyses from the United Kingdom and Ireland showing lower odds of diagnosis in males, and with the hypothesis that females with neurodevelopmental disorders carry a higher burden of rare, high-impact variants, consistent with a female protective model. After adjusting for sex distribution and the additional analyses performed in the genome sequencing arm, the overall yield difference between the two strategies narrowed to 7.3 percent, which no longer reached conventional statistical significance (p = 0.069) — a nuance the authors report transparently.

What sets this trial apart from earlier comparisons is its setting. Most previous studies of genome sequencing relied on centralized reference or research laboratories, raising questions about whether the technology could deliver comparable performance in the decentralized, hospital-based laboratories where most patients are actually seen. The Belgian consortium implemented clinical-grade genome sequencing across five sequencing sites and eight clinical interpretation centers, each using its own validated wet-lab and bioinformatic protocols. Before recruitment, all centers participated in an inter-laboratory ring trial using Genome-In-A-Bottle reference samples, achieving consistently high precision and recall for variant calling despite differences in library preparation kits, fragmentation methods, and reference genome versions. This demonstrated that nationwide, multi-site implementation of clinical genome sequencing is feasible — and that its diagnostic utility in hospital settings may actually exceed that reported in external reference laboratories.

The study was not without limitations. Recruitment fell short of the initial target of 800 participants, reducing statistical power, and the trial was retrospectively registered. Over two-thirds of the cohort had already undergone negative copy-number analysis before enrollment, meaning the CNV detection advantage of genome sequencing was likely underestimated; in a true first-tier setting, where pathogenic copy-number variants are found in roughly 12 percent of patients, the gap in favor of genome sequencing could be wider. Short-read sequencing also remains blind to certain challenges: low-complexity repetitive regions, some structural variants, inversions, complex rearrangements, mosaic variants, and epigenetic abnormalities all persist as blind spots, though long-read technologies promise to address some of these constraints as costs fall.

The implications for clinical practice are substantial. Beyond raw diagnostic yield, genome sequencing consolidates what is currently a fragmented, sequential testing cascade — microarray, exome, and follow-up assays — into a single test that simultaneously detects single nucleotide variants, indels, copy-number variants, structural variants, and repeat expansions. That streamlining reduces turnaround time, a critical factor for critically ill newborns, and preserves the option of reanalysis as knowledge grows: a post hoc targeted look at the recently discovered RNU4-2 gene, implicated in roughly 0.5 percent of neurodevelopmental disorders, immediately yielded one additional diagnosis among the trial’s unsolved genome sequencing samples. With artificial intelligence-driven variant prioritization tools already contributing to the yield gains observed here, and with non-coding variant interpretation maturing rapidly, the authors anticipate the advantage of genome sequencing will only grow — strengthening the case for making it the first-line molecular test for children with unexplained developmental disorders.

Subject of Research: Genome sequencing versus standard of care for diagnosing developmental disorders

Article Title: A nationwide prospective randomized trial for diagnosing developmental disorders demonstrates genome sequencing outperforms standard of care

Article References: A nationwide prospective randomized trial for diagnosing developmental disorders demonstrates genome sequencing outperforms standard of care. (n.d.). https://doi.org/10.1186/s13073-026-01771-2

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01771-2

Keywords: genome sequencing, exome sequencing, developmental disorders, intellectual disability, congenital anomalies, diagnostic yield, randomized controlled trial, clinical genetics, non-coding variants, autosomal dominant inheritance, BeSolveRD trial, Genome Medicine